MarketPulse

retinal disease

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Pharmaceuticals Names Veteran Ophthalmology Executive Campbell as CCO

EyePoint Pharmaceuticals appoints Michael Campbell as Chief Commercial Officer. The ophthalmology veteran brings 30+ years of experience to lead commercial strategy for DURAVYU ahead of 2026 clinical data.
EYPTPhase 3 clinical trialophthalmology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ocular Therapeutix to Release SOL-1 Phase 3 Results for Wet AMD Treatment

Ocular Therapeutix announces Phase 3 results for SOL-1 wet AMD treatment on February 17, 2026. AXPAXLI data presentation follows at Macula Society Annual Meeting.
OCULPhase 3 clinical trialbiopharmaceutical